1386986-16-8

Basic information

• Product Name: 5-difluoromethyl-3-methylpyridine-2-carboxylic acid
• Synonyms: 5-difluoromethyl-3-methylpyridine-2-carboxylic acid
• CAS NO: 1386986-16-8
• Molecular Weight: 187.146
• Mol File: 1386986-16-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-difluoromethyl-3-methylpyridine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-difluoromethyl-3-methylpyridine-2-carboxylic acid(1386986-16-8)
• EPA Substance Registry System: 5-difluoromethyl-3-methylpyridine-2-carboxylic acid(1386986-16-8)

Safety Data

• Hazardous Substances Data: 1386986-16-8(Hazardous Substances Data)

Upstream product

• 1386986-18-0 5-difluoromethyl-3-methyl-pyridine-2-carbonitrile 
• 1386986-17-9 2-chloro-5-difluoromethyl-3-methylpyridine 
• 176433-43-5 6-chloro-5-methylpyridine-3-carboxaldehyde 

Downstream Products

• 1624604-71-2 N-(3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4,5-difluorophenyl)-5-(difluoromethyl)-3-methylpicolinamide 
• 1600507-96-7 N-(3-((6S,7R)-9-amino-6-fluoro-7-methyl-5,5-dioxido-5-thia-8-azaspiro[3.5]non-8-en-7-yl)-4-fluorophenyl)-5-(difluoromethyl)-3-methylpicolinamide 
• 1600508-70-0 N-(3-((5S,6R)-8-amino-5-fluoro-6-methyl-4,4-dioxido-4-thia-7-azaspiro[2.5]oct-7-en-6-yl)-4-fluorophenyl)-5-(difluoromethyl)-3-methyl-2-pyridinecarboxamide 
• 1624605-15-7 N-(3-((4S,6S)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluoro-5-methylphenyl)-5-(difluoromethyl)-3-methylpicolinamide 

Relevant articles and documents

BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free form or in pharmaceutically acceptable salt form, to their preparation, to their medical use and to medicaments comprising them.